

Curriculum Vitae

Name Atsushi Sugioka, MD, PhD

Position and Institute

Designated Professor of the Department of Surgery and International Medical Center, Fujita Health University Hospital, Aichi, Japan.

Education and Training:

1982 Graduated from Keio University School of Medicine
1982-1983 Residency in Department of Surgery, Keio University
1983-1984 Medical Staff in Surgery, Nihon-Kokan Hospital
1984-1985 Medical Staff in Surgery, National Saitama Hospital
1985-1987 Assistant Medical Staff, Department of Surgery, Keio University

Hospital Appointment:

1987-1992 Vice director of Surgery, Hamamatsu Red Cross Hospital

Academic Appointments:

1992-1997 Lecturer, 1st Department of Gastroenterological Surgery,
Fujita Health University School of Medicine.
1997-1999 Assistant Professor, 1st Department of Gastroenterological Surgery,
Fujita Health University School of Medicine.
1999-2005 Associate Professor, 1st Department of Gastroenterological Surgery,
Fujita Health University School of Medicine.
2005-2016 Professor and Chair, Department of Hepatosplenic Surgery, Fujita Health
University School of Medicine.
2015-2017 Vice president, Fujita Health University
2016-2017 Professor and Chair, Department of Hepatopancreatobiliary Surgery, Fujita
Health University School of Medicine.
2017-2021 Professor and Chair, Department of Surgery, Fujita Health University School of
Medicine.
2021-date Designated professor, Department of Surgery and International Medical Center,
Fujita Health University Hospital.

Brief introduction

Dr. Atsushi Sugioka is a Hepatopancreatobiliary and liver transplant surgeon. Now he is the designated professor of the department of surgery and international medical center of Fujita Health University Hospital in Aichi, Japan.

As a hepatopancreatobiliary surgeon, He has a great interest in standardization of all kinds of hepatobiliary surgery including laparoscopic and robotic minimally invasive liver resection. Recently, he proposed a novel liver anatomy based on Laennec's capsule that is expected to bring innovative changes. He also introduced several unique and effective neoadjuvant chemotherapy protocols for far-advanced perihilar cholangiocarcinoma and hepatocellular carcinoma with massive tumor thromboses which contributed to improve prognoses.

As a liver transplant surgeon, he performs living related liver transplantation and devoted to elucidating the mechanism of immunological tolerance using the unique orthotopic mice liver transplantation model.

On the other hand, as a basic researcher he also dedicated himself to obtain numerous novel human monoclonal antibodies against hepatocellular carcinoma using human antibody phage library using the novel comprehensive isolation technique (ICOS method). He obtained 158 kinds of human monoclonal antibodies and revealed 19 kinds of novel target antigens on cancer cell surfaces, that is expected to establish personalized medicine for HCC.